Abstract
Using national data (2001-2003), this study explored the risk of acute myocardial infarction (AMI), angina, stroke and transient ischaemic attack (TIA) in long-term users of rofecoxib and celecoxib in Taiwan and compared this data with that for those using meloxicam. Patients included in the study had used celecoxib, rofecoxib or meloxicam for at least 180 days. Data were taken from National Health Insurance database for the period from 2001 to 2003. Main outcome measurements were the occurrence of AMI, angina, stroke or TIA after the initiation of long-term continuous use of these drugs. Person-time exposures and hazard ratios (HRs) were calculated based on data from 9602 eligible patients. In patients without a history of a cardiovascular event within the year before drug treatment began, the overall rates of AMI, angina, stroke and TIA were 1.1%, 0.6%, 2.0% and 0.6%, respectively. In those with cardiovascular events in the year before treatment began, the overall rates of AMI, angina, stroke and TIA were 5.0%, 4.8%, 6.6% and 5.8%, respectively. Compared with meloxicam users, celecoxib users had lower HRs for the development of AMI (HR 0.78, 95% CI 0.63, 0.96) and stroke (HR 0.81, 95% CI 0.70, 0.93). Rofecoxib users were at n...Continue Reading
References
Aug 11, 2001·The New England Journal of Medicine·G A FitzGerald, C Patrono
Oct 18, 2002·Lancet·Wayne A RayMarie R Griffin
Jan 29, 2003·Circulation·Rémy ChenevardFrank Ruschitzka
May 23, 2003·Anesthesia and Analgesia·Noor M Gajraj
Jun 28, 2003·The Journal of Thoracic and Cardiovascular Surgery·Elisabeth OttUNKNOWN Ischemia Research and Education Foundation (IREF) Investigators
Aug 25, 2004·Lancet·Michael E FarkouhUNKNOWN TARGET Study Group
Oct 8, 2004·The New England Journal of Medicine·Eric J Topol
Dec 8, 2004·Lancet·Peter JüniMatthias Egger
Dec 21, 2004·The New England Journal of Medicine·Wayne A RayC Michael Stein
Feb 3, 2005·Annals of Internal Medicine·Stephen E KimmelBrian L Strom
Feb 12, 2005·Lancet·David J GrahamWayne A Ray
Feb 17, 2005·The New England Journal of Medicine·Robert S BresalierUNKNOWN Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators
Feb 17, 2005·The New England Journal of Medicine·Scott D SolomonUNKNOWN Adenoma Prevention with Celecoxib (APC) Study Investigators
Mar 24, 2005·Rheumatology·S BernatskyS Suissa
Citations
Mar 20, 2010·International Journal of Public Health·Pen-Jen WangChristy Pu
Dec 15, 2007·Rheumatology International·R TsutsumiT Nakamura
Apr 12, 2012·Proceedings of the National Academy of Sciences of the United States of America·Zhou YuGarret A FitzGerald
Jul 6, 2007·BMC Gastroenterology·Michael LoydPhilip Jacobs
Jan 10, 2013·PloS One·Attila KristófLászló Virág
Aug 7, 2012·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Victor A Kiri
Aug 28, 2010·American Journal of Pharmaceutical Education·Jack E Fincham
Jan 23, 2013·Clinical Drug Investigation·José Pedro Henriques PatrícioPedro Carlos Santos de Melo
Mar 5, 2016·Expert Opinion on Investigational Drugs·Nikolaos PapageorgiouDimitris Tousoulis
Dec 18, 2014·Inflammopharmacology·Waheed Asghar, Fakhreddin Jamali
Aug 28, 2007·Journal of Science and Medicine in Sport·John Orchard
Jan 11, 2007·Clinical Therapeutics·Weng-Foung HuangYi-Wen Tsai
Oct 6, 2011·Pharmacoepidemiology and Drug Safety·Cristina Varas-LorenzoSusana Perez-Gutthann
Jul 1, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Stephen P MotskoJason Worchel
Oct 17, 2017·Rheumatology International·Deepan DalalDavid Felson
Sep 17, 2020·Canadian Journal of Physiology and Pharmacology·Bence PásztiIstván Koncz
Nov 10, 2015·European Journal of Pharmacology·Kim GilbertGuy Rousseau